16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41% ...
The Alpacca trial features a robust sample size of 480 patients with 1:1 randomization, which Clear Street believes strengthens the likelihood that firmonertinib will deliver positive, ...
The owner of an alpaca that is said to have tuberculosis and therefore is set to be culled, has claimed on ITV's This Morning that he (Geronimo) has not actually failed a validated test.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback